Your browser doesn't support javascript.
loading
Expanding the clinicopathological spectrum of succinate dehydrogenase-deficient renal cell carcinoma with a focus on variant morphologies: a study of 62 new tumors in 59 patients.
Fuchs, Talia L; Maclean, Fiona; Turchini, John; Vargas, A Cristina; Bhattarai, Selina; Agaimy, Abbas; Hartmann, Arndt; Kao, Chia-Sui; Ellis, Carla; Bonert, Michael; Leroy, Xavier; Kunju, Lakshmi P; Schwartz, Lauren; Matsika, Admire; Williamson, Sean R; Rao, Priya; Divatia, Mukul; Guarch, Rosa; Algaba, Ferran; Balancin, Marcelo L; Zhou, Ming; Samaratunga, Hemamali; da Cunha, Isabela Werneck; Brimo, Fadi; Ryan, Andrew; Clouston, David; Aron, Manju; O'Donnell, Marie; Chan, Emily; Hirsch, Michelle S; Moch, Holger; Pang, Chun-Yin; Wah, Cheuk; Yin, Weihua; Perry-Keene, Joanna; Yilmaz, Asli; Chou, Angela; Clarkson, Adele; van der Westhuizen, Gerhard; Morrison, Ella; Zwi, Jonathan; Hes, Ondrej; Trpkov, Kiril; Gill, Anthony J.
Affiliation
  • Fuchs TL; Sydney Medical School, The University of Sydney, Sydney, Australia.
  • Maclean F; Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, St Leonards, NSW, Australia.
  • Turchini J; NSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, NSW Health Pathology, St Leonards, NSW, Australia.
  • Vargas AC; Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, St Leonards, NSW, Australia.
  • Bhattarai S; Anatomical Pathology, Douglass Hanly Moir Pathology, Sonic Healthcare, Macquarie Park, NSW, Australia.
  • Agaimy A; Discipline of Pathology, Macquarie Medical School, Macquarie University, Macquarie Park, NSW, Australia.
  • Hartmann A; Sydney Medical School, The University of Sydney, Sydney, Australia.
  • Kao CS; Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, St Leonards, NSW, Australia.
  • Ellis C; Anatomical Pathology, Douglass Hanly Moir Pathology, Sonic Healthcare, Macquarie Park, NSW, Australia.
  • Bonert M; Discipline of Pathology, Macquarie Medical School, Macquarie University, Macquarie Park, NSW, Australia.
  • Leroy X; Sydney Medical School, The University of Sydney, Sydney, Australia.
  • Kunju LP; Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, St Leonards, NSW, Australia.
  • Schwartz L; Anatomical Pathology, Douglass Hanly Moir Pathology, Sonic Healthcare, Macquarie Park, NSW, Australia.
  • Matsika A; Discipline of Pathology, Macquarie Medical School, Macquarie University, Macquarie Park, NSW, Australia.
  • Williamson SR; Leeds Teaching Hospital, Leeds, UK.
  • Rao P; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
  • Divatia M; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
  • Guarch R; Stanford University Medical Center, Stanford, CA, USA.
  • Algaba F; Northwestern University, Chicago, IL, USA.
  • Balancin ML; McMaster University, Hamilton, Ontario, Canada.
  • Zhou M; Institut de Pathologie, Centre de Biologie-Pathologie, CHRU, Lille, France.
  • Samaratunga H; University of Michigan, Ann Arbor, MI, USA.
  • da Cunha IW; University of Pennsylvania, Philadelphia, PA, USA.
  • Brimo F; Mater Health, Brisbane, QLD, Australia.
  • Ryan A; University of Queensland, Brisbane, QLD, Australia.
  • Clouston D; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic Cleveland, Ohio, OH, USA.
  • Aron M; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • O'Donnell M; Houston Methodist Hospital, Houston, TX, USA.
  • Chan E; Complejo Hospitalario de Navarra, Navarra, Spain.
  • Hirsch MS; Fundació Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain.
  • Moch H; Oncocentro Foundation, Sao Paulo, Brazil.
  • Pang CY; Tufts Medical Center, Boston, MA, USA.
  • Wah C; University of Queensland, Brisbane, QLD, Australia.
  • Yin W; Aquesta Pathology, Toowong, QLD, Australia.
  • Perry-Keene J; Institute of Pathology, Rede D'OR-São Luiz and D'Or Institute for Research and Education (IDOR), São Paulo, Brazil.
  • Yilmaz A; McGill University, Montreal, Canada.
  • Chou A; TissuPath Pathology, Melbourne, VIC, Australia.
  • Clarkson A; TissuPath Pathology, Melbourne, VIC, Australia.
  • van der Westhuizen G; University of Southern California, Los Angeles, CA, USA.
  • Morrison E; NHS Lothian, Edinburgh, Scotland, UK.
  • Zwi J; University of California San Francisco, San Francisco, CA, USA.
  • Hes O; Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
  • Trpkov K; Department of Pathology and Molecular Pathology, University Hospital Zurich and University Zurich, Zurich, Switzerland.
  • Gill AJ; St. Teresa's Hospital, Kowloon, Hong Kong, SAR, China.
Mod Pathol ; 35(6): 836-849, 2022 06.
Article in En | MEDLINE | ID: mdl-34949766
ABSTRACT
Most succinate dehydrogenase (SDH)-deficient renal cell carcinomas (RCCs) demonstrate stereotypical morphology characterized by bland eosinophilic cells with frequent intracytoplasmic inclusions. However, variant morphologic features have been increasingly recognized. We therefore sought to investigate the incidence and characteristics of SDH-deficient RCC with variant morphologies. We studied a multi-institutional cohort of 62 new SDH-deficient RCCs from 59 patients. The median age at presentation was 39 years (range 19-80), with a slight male predominance (MF = 1.61). A relevant family history was reported in 9 patients (15%). Multifocal or bilateral tumors were identified radiologically in 5 patients (8%). Typical morphology was present at least focally in 59 tumors (95%). Variant morphologies were seen in 13 (21%) and included high-grade nuclear features and various combinations of papillary, solid, and tubular architecture. Necrosis was present in 13 tumors, 7 of which showed variant morphology. All 62 tumors demonstrated loss of SDHB expression by immunohistochemistry. None showed loss of SDHA expression. Germline SDH mutations were reported in all 18 patients for whom the results of testing were known. Among patients for whom follow-up data was available, metastatic disease was reported in 9 cases, 8 of whom had necrosis and/or variant morphology in their primary tumor. Three patients died of disease. In conclusion, variant morphologies and high-grade nuclear features occur in a subset of SDH-deficient RCCs and are associated with more aggressive behavior. We therefore recommend grading all SDH-deficient RCCs and emphasize the need for a low threshold for performing SDHB immunohistochemistry in any difficult to classify renal tumor, particularly if occurring at a younger age.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Kidney Neoplasms Type of study: Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Mod Pathol Journal subject: PATOLOGIA Year: 2022 Type: Article Affiliation country: Australia

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Kidney Neoplasms Type of study: Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Mod Pathol Journal subject: PATOLOGIA Year: 2022 Type: Article Affiliation country: Australia